Viatris (VTRS) just announced a research partnership with Locus Biosciences focused on fighting antibiotic-resistant eye infections. The companies plan to leverage advanced AI and synthetic biology to create targeted bacteriophage treatments. The agreement positions Viatris in a promising innovation space.

After a tough start to the year for shareholders, Viatris has seen its share price rebound 17.3% over the past 90 days, with momentum building after recent collaboration and board moves. However, the one-year total shareholder return remains slightly negative, reflecting the longer-term challenges and opportunities facing the business.

If innovative partnerships are on your radar, now is a good time to see what else is happening in the sector by exploring the See the full list for free.

With shares still trading at a discount to analyst price targets while also showing signs of renewed momentum, investors now face a key question: is the current price a compelling entry point, or is future growth already reflected?

Most Popular Narrative: 12.3% Undervalued

With Viatris closing at $10.53 and the most widely followed narrative assigning fair value at $12.00, the narrative signals there could be more upside if projections pan out. All eyes are on how much of its anticipated earnings rebound is already reflected in the current price.

The company is well positioned to benefit from sustained demand growth due to global population aging and increasing chronic disease prevalence. This is demonstrated by positive late-stage pipeline developments in chronic disease, pain, and ophthalmology, which sets the stage for long-term revenue growth through new branded and generic launches in large, underserved markets.

Want to see what’s fueling this valuation call? Analysts are betting on a future profit turnaround and an ambitious margin leap that might surprise you. Intrigued by the numbers behind this optimism? Check out the full financial breakdown that shapes this fair value.

Result: Fair Value of $12.00 (UNDERVALUED)

However, ongoing pressure from generic competition and persistent operational challenges could quickly reshape the outlook if market share declines or efficiency falters.

Build Your Own Viatris Narrative

If you see things differently or want to dive deeper into the numbers yourself, it’s easy to craft your own narrative in just a few minutes: Do it your way

A great starting point for your Viatris research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.

Looking for More Smart Investment Ideas?

Don’t let opportunities pass you by. Use these powerful tools to spot trends early, seize advantage, and keep your portfolio one step ahead of the market.

• Capture income potential and strengthen your financial base by scanning for yields over 3% in these 18 dividend stocks with yields > 3%.
• Capitalize on breakthroughs in AI and machine intelligence by tapping into these 26 AI penny stocks with the strongest momentum and future prospects.
• Power up your returns by finding hidden gems with growth potential using these 842 undervalued stocks based on cash flows, and act before they’re on everyone’s radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.